GLPwatch
Papers (12034)
Page 187 of 201, ranked by citation count.
- The GLP-1 Ceiling and GIP Dividend: Unraveling the Cardio-Metabolic Paradox in SURPASS-CVOT.
- Differential Anti-Inflammatory Effects of Semaglutide and Tirzepatide in Experimental Diabetes Mellitus.
- Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer's Disease.
- Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction.
- dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
- Broad glucagon-like peptide-1 (GLP-1) receptor distribution enhances glutamatergic transmission throughout the mouse cerebellar cortex.
- Semaglutide: An emerging treatment option for patients with obesity related HFpEF.
- Oral Delivery of Liraglutide Formulated with PLGA for Sustained Obesity Management.
- Medical Treatments for Obesity: What Does the Future Have in Store?
- Glucagon-Like Peptide-1 (GLP-1a) Receptor Agonist Use in Patients Presenting for Gastroenterology Procedures: A Review of Concerns.
- External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.
- Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.
- Fathoming the Role of Semaglutide in Obesity Therapeutics.
- Attitudes Toward Injectable GLP-1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals.
- Weekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies.
- Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
- Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.
- Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
- [Liraglutide in the treatment of obesity : a multidisciplinary approach].
- Adultes en surpoids ou obèses : effets du sémaglutide.
- GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.
- [A case of an elderly diabetic patient with dementia effectively treated with weekly exenatide].
- Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.
- Use of semaglutide and tirzepatide among people with multiple sclerosis.
- Exenatide at mealtimes in type 1 diabetes-no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists.
- Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.
- Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency.
- A Revolution in Medicine and Surgery Has Begun.
- Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.
- Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.
- [In Process Citation].
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.
- Can early use of insulin, GLP-1 halt diabetes progression?
- Semaglutide Once Weekly Helps Adolescents Lose Weight, but 4% Developed Acute Cholelithiasis.
- Drug used to treat diabetes may get ok for weight loss.
- Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
- Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.
- Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.
- The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.
- Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.
- HIPPOCAMPAL GANGLIOSIDE COMPOSITION IS ALTERED BY METFORMIN AND LIRAGLUTIDE TREATMENT IN A HIGH-FAT HIGH-SUGAR DIET RAT MODEL.
- [Does a higher dose of oral semaglutide treatment make sense?]
- [Exenatide promotes cholesterol efflux in pancreatic tissue of obese diabetic rats].
- Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.
- Time to Benefit of Incretin-Based Therapies in Adiposity-Related Heart Failure With Mildly Reduced or Preserved Ejection Fraction: a Systematic Review and Meta-Analysis.
- [Obesity treatment with semaglutide].
- Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
- Clarifying the interpretation of semaglutide's impact in the FLOW study.
- Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
- [GLP-1 agonists - new kid on the block in nephrology].
- GLP-1 and GLP-1/GIP agonists in psoriasis: A real-world cohort study on healthcare resource usage.
- Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers.
- Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.
- Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
- Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.
- Meeting of the minds: Send your stories.
- Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 <i>post hoc</i> analysis.
- Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy.
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.